

**Draft agenda**  
**27<sup>th</sup> meeting of the Biocidal Products Committee (BPC)**  
**16-18 October 2018**  
**ECHA Conference Centre, Annankatu 18, Helsinki**  
**Starts on 16 October at 09:30,**  
**ends on 18 October at 16:00**

1. – Welcome and apologies

2. – Agreement of the agenda

BPC-A-27-2018\_rev1  
*For agreement*

3. – Declarations of potential conflicts of interest to agenda items

4. – Agreement of the minutes and review of actions from BPC-26

BPC-M-26-2018  
*For agreement*

5. – Administrative issues

5.1. Housekeeping issues

*For information*

5.2. Other administrative issues and report from other Committees

BPC-27-2018-01  
*For information*

6. – Work programme for BPC

6.1. Revised BPC Work Programme 2018-2019

BPC-27-2018-02  
*For information*

**6.2. Outlook for BPC**

BPC-27-2018-03  
***For information***

**6.3. Status harmonised classification and labelling for active substances**

BPC-27-2018-04  
***For information***

**7. – Applications for approval of active substances\***

**7.1. Procedural and administrative aspects:**

**7.1.1. Template BPC opinion for active substance approval**

BPC-27-2018-05  
***For information***

**7.1.2. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval**

BPC-27-2018-06  
***For information***

**7.2. Draft BPC opinion on silver zinc zeolite for PT 2, 4, 7 and 9**

*Previous discussion(s): TM-II-2013, TM-IV-2013, WG-III-2015, WG-III-2016, WG-V-2016, WG-V-2017*

PT 2: BPC-27-2018-08A, B, C, BPC-27-2018-35

PT 4: BPC-27-2018-09A, 08B, 09C

PT 7: BPC-27-2018-10A, 08B, 10C

PT 9: BPC-27-2018-11A, 08B, 11C

***For agreement***

**7.3. Draft BPC opinion on silver zeolite for PT 2, 4, 7 and 9**

*Previous discussion(s): WG-V-2017*

PT 2: BPC-27-2018-12A, B, C

PT 4: BPC-27-2018-13A, 12B, 13C

PT 7: BPC-27-2018-14A, 12B, 14C

PT 9: BPC-27-2018-15A, 12B, 15C

***For adoption***

---

\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft assessment report (AR) which may cover more than one PT (denoted by B) and a document containing open issues covering all the PTs to be discussed for that substance (denoted by C).

**7.4. Draft BPC opinion on silver copper zeolite for PT 2, 4, 7 and 9**

*Previous discussion(s): WG-V-2017*

PT 2: BPC-27-2018-16A, B, C

PT 4: BPC-27-2018-17A, 16B, 17C

PT 7: BPC-27-2018-18A, 16B, 18C

PT 9: BPC-27-2018-19A, 16B, 19C

***For adoption***

**7.5. Draft BPC opinion on silver sodium hydrogen zirconium phosphate for PT 2, 4, 7 and 9**

*Previous discussion(s): WG-V-2017*

PT 2: BPC-27-2018-20A, B, C

PT 4: BPC-27-2018-21A, 20B, 21C

PT 7: BPC-27-2018-22A, 20B, 22C

PT 9: BPC-27-2018-23A, 20B, 23C

***For adoption***

**7.6. Revised Assessment Report following the submission of data after active substance approval:**

**7.6.1. Formaldehyde for PT 3**

BPC-27-2018-24

***For agreement***

**7.6.2. Margosa extract, cold-pressed oil of *Azadirachta indica* seeds without shells extracted with super-critical carbon dioxide for PT 19**

BPC-27-2018-25

***For agreement***

**7.6.3. 2-octyl-isothiazol-3(2H)-one (OIT) for PT 8**

BPC-27-2018-26

***For agreement***

**7.6.4. *epsilon*-Momfluorothrin for PT 18**

BPC-27-2018-27

***For agreement***

**7.6.5. *Bacillus thuringiensis* subsp. *kurstaki*, serotype 3a3b, strain ABTS-351 for PT 18**

BPC-27-2018-28

***For agreement***

**7.7. Requesting further information as new test guidelines become available**

BPC-27-2018-29

***For agreement***

**7.8. Terminology primary and secondary exposure in the BPC opinion**  
BPC-27-2018-30  
*For agreement*

**7.9. Systematic literature review for ED assessment**  
BPC-27-2018-07  
*For discussion*

#### **Item 8 – Union authorisation\*\***

**8.1 Update on Union authorisation**

**8.2 Draft BPC opinions on Union authorisation applications for a product family containing iodine / PVP-iodine**  
*Previous discussion(s): WG-IV-2018*  
BPC-27-2018-31A, B, C, D  
*For adoption*

**8.3 Working procedure for applications for major change of a Union authorisation**  
BPC-27-2018-32  
*For agreement*

**8.4 Union authorisation major change applications: cooperation during the evaluation stage**  
BPC-27-2018-33  
*For agreement*

#### **Item 9 – Article 38 opinions**

**9.1 Draft BPC opinion on “Questions on unresolved objections during mutual recognition of a PT 18 biocidal product family containing 1R-trans phenothrin for use against ants”**  
BPC-27-2018-34A  
*For adoption*

---

\*\* For the discussions of the draft BPC opinions at least the following documents will be distributed: a draft BPC opinion (denoted by A), a draft Summary of Product Characteristics (SPC) (denoted by B), a draft product assessment report (PAR) (denoted by C) and a document containing open issues to be discussed for the biocidal product or biocidal product family (denoted by D).

**Item 10 – Any other business**

**Item 11 – Action points and conclusions**

*For agreement*

**Provisional time schedule for the  
27<sup>th</sup> meeting of the Biocidal Products Committee (BPC)  
ECHA Conference Centre, Annankatu 18, Helsinki  
16 October 2018: starts at 09:30; 18 October 2018 ends at 16:00**

Please note that the time schedule indicated below is provisional and subject to possible change. The schedule is distributed to participants on a preliminary basis. If needed, follow-up discussions may take place on the following day for BPC opinions.

**Tuesday 16 October: morning session**

Items 1-5	Opening items and administrative issues
Item 6	Work programme of the BPC 2018-2019
Item 7.1	Procedural and administrative aspects: 7.1.1. Template BPC opinion for active substance approval 7.1.2. Catalogue of specific conditions and elements to be taken into account at the product authorisation stage for active substance approval
Item 7.7	Requesting further information as new test guidelines become available
Item 7.8	Terminology primary and secondary exposure in the BPC opinion
Item 7.9	Systematic literature review for ED assessment

**Tuesday 16 October: afternoon session**

Item 7.2-7.5	BPC opinions on silver: 7.2. Draft BPC opinion on silver zinc zeolite for PT 2, 4, 7 and 9 7.3. Draft BPC opinion on silver zeolite for PT 2, 4, 7 and 9 7.4. Draft BPC opinion on silver copper zeolite for PT 2, 4, 7 and 9 7.5. Draft BPC opinion on silver sodium hydrogen zirconium phosphate for PT 2, 4, 7 and 9
--------------	---

**Wednesday 17 October: morning session**

Item 7.2-7.5	Draft BPC opinions on silver (continued)
--------------	--

**Wednesday 17 October: afternoon session**

Item 7.2-7.5	Draft BPC opinions on silver (continued)
--------------	--

**Thursday 18 October: morning session**

- Item 7.6 Revised Assessment Report following the submission of data after active substance approval:
- 7.6.1. Formaldehyde for PT 3
  - 7.6.2. Margosa extract, cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide for PT 19
  - 7.6.3. 2-octyl-isothiazol-3(2H)-one (OIT) for PT 8
  - 7.6.4. epsilon-Momfluorothrin for PT 18
  - 7.6.5. Bacillus thuringiensis subsp. kurstaki, serotype 3a3b, strain ABTS-351for PT 18
- Item 8.1 Update on Union authorisation
- Item 8.2 Draft BPC opinions on Union authorisation applications for a product family containing iodine / PVP-iodine
- Item 8.3 Working procedure for applications for major change of a Union authorisation
- Item 8.4 Union authorisation major change applications: cooperation during the evaluation stage

**Thursday 18 October: afternoon session**

- Item 9.1 Draft BPC opinion on "Questions on unresolved objections during mutual recognition of a PT 18 biocidal product family containing 1R-trans phenothrin for use against ants"
- Item 10 AOB
- Item 11 Action points and conclusions

End of meeting

oOo